Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.33 |
| ▸ | BRAF | P15056 | 3/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30869774 | 0.90 | PARP1 (0.38) | ABL1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30869697 | 0.85 | BRAF (0.42) | ABL1RETBRAF | |
| SCHEMBL30869797 | 0.82 | FGFR1 (0.39) | ABL1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30869536 | 0.78 | HSD11B1 (0.40) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30869490 | 0.77 | PIK3CD (0.42) | ABL1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30869457 | 0.77 | PIK3CD (0.42) | ABL1KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL30869706 | 0.75 | CHRNA7 (0.38) | ABL1RETBRAF | |
| SCHEMBL30869525 | 0.75 | ATR (0.35) | KDRFGFR1FGFR2FGFR4FGFR3 | |
| SCHEMBL30869548 | 0.74 | BRAF (0.42) | ABL1CREBBPRETBRAF | |
| SCHEMBL30869668 | 0.71 | NUDT1 (0.39) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4583868-A2 | DYNAMIN ACTIVATORS | Walden Biosciences, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024054661-A2 | DYNAMIN ACTIVATORS | WALDEN BIOSCIENCES (US) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070880-A1 | DYNAMIN ACTIVATORS | DNM1, DNM1L, DNM2 | ABL1 826/4885KDR 2528/4885FGFR1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.